Pfizer Inc. (PFE): Are Hedge Funds Right About This Stock?

The elite funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don’t follow. Because of their pay structures, they have strong incentive to do the research necessary to beat the market. That’s why we pay close attention to what they think in small cap stocks. In this article, we take a closer look at Pfizer Inc. (NYSE:PFE) from the perspective of those elite funds.

Is Pfizer Inc. (NYSE:PFE) worth your attention right now? The smart money is taking a bearish view, as the number of bullish hedge fund bets fell by 11 between July and September. Pfizer was in 83 hedge funds’ portfolios at the end of September. At the end of this article we will also compare PFE to other stocks including Anheuser-Busch InBev NV (ADR) (NYSE:BUD), Royal Dutch Shell plc (ADR) (NYSE:RDS), and Chevron Corporation (NYSE:CVX) to get a better sense of its popularity.

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 18% gains over the past 12 months, more than doubling the 8% returns enjoyed by the S&P 500 ETFs.

pio3 / Shutterstock.com

Now, we’re going to take a look at the key action surrounding Pfizer Inc. (NYSE:PFE).

How have hedgies been trading Pfizer Inc. (NYSE:PFE)?

As stated earlier, there were 83 funds tracked by Insider Monkey long Pfizer, down by 12% from the end of June. With hedgies’ capital changing hands, there exists an “upper tier” of notable hedge fund managers who were increasing their holdings meaningfully (or already accumulated large positions).

When looking at the institutional investors followed by Insider Monkey, Ken Fisher’s Fisher Asset Management has the biggest position in Pfizer Inc. (NYSE:PFE), worth close to $1.08 billion, accounting for 1.9% of its total 13F portfolio. Sitting at the No. 2 spot is Maverick Capital, managed by Lee Ainslie, which holds a $724.1 million position; the fund has 8.6% of its 13F portfolio invested in the stock. Some other professional money managers that are bullish encompass Ric Dillon’s Diamond Hill Capital, Cliff Asness’s AQR Capital Management and Jim Simons’ Renaissance Technologies.